You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥將於2021 AACR年會公佈最新腫瘤治療自研抗體
格隆匯 04-15 17:23

和鉑醫藥(股票代碼:02142.HK)是一家專注於腫瘤及免疫性疾病領域創新藥研發及商業化的全球化生物製藥企業。公司通過自主研發、聯合開發及多元化的合作模式快速拓展創新藥研發管線。近期,2021年美國癌症研究學會(AACR)大會在線召開,和鉑醫藥於大會上公佈了基於自有抗體技術平台H2L2研發的全人源單克隆抗體B7H7。該抗體是和鉑自研的全新免疫治療藥物,和鉑在會上展示了其獨特的作用機制和強大的抗腫瘤效果。

最新發現

和鉑醫藥利用具有自主知識產權的全人源抗體技術平台H2L2研發出B7H7抗體,該抗體具有全人源、高親和力和高生物活性的特點。B7H7抗體通過阻斷B7H7對免疫細胞的抑制作用,解除免疫耐受,促進免疫細胞活化;體內動物實驗顯示單藥具有很強的抗腫瘤作用。

和鉑醫藥的B7H7抗體是一種全新的免疫治療藥物,具有廣闊應用前景,有可能應用於PD-L1/PD1抗體耐受的病人,也可與現有的免疫治療手段聯用,進一步提高療效。

關於B7H7

B7家族分子在調控免疫細胞活化的過程中起重要作用,其中包括著名的PD-L1分子,針對PD-L1/PD1的免疫治療已經給腫瘤治療帶來了新的突破。B7H7是最新發現的B7家族分子成員,作為一個免疫檢查點,B7H7會顯著抑制免疫細胞的活化。腫瘤細胞可以利用B7H7,抑制免疫細胞活化,從而逃避免疫監控。B7H7在許多腫瘤,特別是PD-L1陰性的腫瘤中高表達,與腫瘤的惡性程度和不良預後有密切關係。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account